Grant opportunity · PAR-25-184
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
Who can apply (as listed)
- For-profit organizations (other than small businesses)
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- County governments
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
- Native American tribal governments (federally recognized)
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
- Independent school districts
- Public housing authorities / Indian housing authorities
- State governments
- City or township governments
- Native American tribal organizations (other than federally recognized governments)
- Small businesses
- Special district governments
- Others (see the opportunity text)
NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.
Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.
GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.